Supernus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Supernus Pharmaceuticals news
10.05.2022
Supernus Pharmaceuticals' GAAP net income for 3 months of 2022 was $25.616 million, up 4.5 times from $5.694 million in the previous year. Revenue increased 16.5% to $152.506 million from $130.932 million a year earlier.
Source: 
ir.supernus.com
ir.supernus.com
14.04.2022
Supernus Pharmaceuticals' GAAP net income for 2021 was $53.424 million, down 2.4 times from $126.95 million in the previous year. Revenue increased 11.4% to $579.775 million from $520.397 million a year earlier.
Source: ir.supernus.com
ir.supernus.com
24.11.2021
Supernus Pharmaceuticals has completed its $400 million acquisition of Adamas Pharmaceuticals. The company has developed GOCOVRI, one of two Adamas drugs approved by the FDA for the treatment of Parkinson's disease. If GOCOVRI sales reach $375 million by 2025, Supernus will pay an additional $50 million. Potential synergies in the first year of the deal coul...
Source: ir.supernus.com
ir.supernus.com
04.11.2021
Supernus Pharmaceuticals' GAAP net income for 9M 2021 was $50.982 million, down 47% from $96.182 million in the previous year. Revenue increased 11.6% to $420.725 million compared to $376.84 million a year earlier.
Source: ir.supernus.com
ir.supernus.com
General information
| Company name | Supernus Pharmaceuticals |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 1550 E GUDE DR ROCKVILLE MD 20850 301-838-2500 |
| Mailing address | 1550 E GUDE DR ROCKVILLE MD 20850 |
| Website | www.supernus.com |
| Information disclosure | www.sec.gov |
English (US) 